Uni-Bio Science Group Limited is pleased to announce the acceptance of its marketing application for Diquafosol Sodium eye drops by the China National Medical Products Administration (“NMPA”) on 23 January 2024, with the acceptance number “CYHS2400318“.
2024-01-23
View details
Uni-Bio Science Group Limited is excited to announce that the China National Medical Products Administration ("NMPA") has officially approved the marketing application for BOGUTAI® (teriparatide injection) on January 16, 2024. This significant milestone h
2024-01-22
View details
Uni-Bio Science 2023 Interim Results，Achieved Record High Profit of HK$39.4M，Driven by Scale-Up Operations and Remarkable Growth in Marketed Drugs，Expanding Multiple Channels and Diverse Commercialization for New Products
2023-08-29
View details
Uni-Bio Science Announces 2022 Annual Results，Record High Turnover of HK$440.3 Million and HK$38.5 Million Profit Achieved Expanding Portfolio with New Drug Innovations and Strategic R&D Partnerships
2023-03-28
View details
From February 23, Uni-Bio Science Group's 2023 Annual Strategy Conference was held in Beijing, attended by the Chairman, CEO, heads and colleagues of the BU.
2023-03-13
View details
京公网安备 11011402013046号京ICP备17029593号-2
